Follow The Filings

QTTB Q32 Bio Inc.

Health Care, filed as Q32 BIO INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 2 Owners
  • Max 1.1%
  • $12M
  • 1 new 1 reduce

In 2026 Q2 Nathan Fischel opened a position in Q32 Bio, while James Silverman trimmed.

Who owns this now

Largest portfolio weights among holders, up to 1.1% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Reduce 1.1%
  2. Nathan Fischel New 0.08%

Who owns QTTB

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management 1.1% Reduce −25.9% 931,000 $12M History
Nathan Fischel, Dafna Capital Management 0.08% New 0.08% 32,896 $419K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by QTTB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All QTTB insider trades
  • $30M bought by 2 insiders
  • $109K sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Diyong Xu Director
    Buy
    $15M 1,875,000 shares at $8.00 New stake
    Traded May 28 Filed Jun 1
    ↗
  2. Jodie Pope Morrison CEO
    Sale
    $78K 22,506 shares at $3.46 19% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025
    ↗
  3. Lee Kalowski CFO
    Sale
    $31K 9,072 shares at $3.46 19% of stake
    Traded Dec 2, 2025 Filed Dec 4, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 9 sales to cover taxes, 6 stock grants, and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
424B3 Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.16M — —
Net income -$112.96M -$47.73M $29.82M
Net margin * -9771.7% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $83.91M $81.88M $55.05M
Total non-current assets * $0.65M $10.46M $6.73M
Total assets $84.56M $92.33M $61.78M
Total current liabilities $11.57M $16.46M $11.35M
Total non-current liabilities * $0M $70.19M $8.42M
Total equity $72.99M $5.68M $42.01M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$96.23M -$67.72M -$33.54M
Cash from investing $101.33M $19.92M $7M
Cash from financing $0.184M $95.14M -$3.12M
Net change in cash * $5.28M $47.35M -$29.67M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.